Xenon Pharmaceuticals
XENE
21 hedge funds and large institutions have $32M invested in Xenon Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
16% less funds holding
Funds holding: 25 → 21 (-4)
20% less capital invested
Capital invested by funds: $39.9M → $32M (-$7.89M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$1.56M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$143K |
| 3 |
Renaissance Technologies
New York
|
+$101K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$68.6K |
| 5 |
LWIC
Leith Wheeler Investment Counsel
Vancouver,
British Columbia, Canada
|
+$12.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$2.94M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$518K |
| 3 |
JC
JBF Capital
Aspen,
Colorado
|
-$480K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$128K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Walleye Trading
New York
| – | -$2K | -300 | Closed |
|
XENE Hedge Fund Activity: Q2 2016 in Review
21 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2016, worth a combined $32M — down 20% from $39.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of XENE and 1 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Perceptive Advisors, adding an estimated $1.56M. The largest seller was Visium Asset Management, exiting entirely with an estimated $2.94M sold.
- 21 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2016, down from 25 in Q1 2016.
- Funds reported $32M of Xenon Pharmaceuticals stock for Q2 2016, down 20% quarter-over-quarter.
- 1 fund opened new Xenon Pharmaceuticals positions in Q2 2016 and 5 closed out, a net change of -4 holders.
- The largest Xenon Pharmaceuticals buyer in Q2 2016 was Perceptive Advisors, an estimated $1.56M added.
- The largest Xenon Pharmaceuticals seller in Q2 2016 was Visium Asset Management, an estimated $2.94M sold.
Based on aggregated 13F filings for Q2 2016.